ELEVAI Labs Inc. (ELAB) AI Stock Analysis

• Market Cap: $2.85M
• Dividend Yield: N/A
• Average Volume (3M): 283.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 18
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -409.35
• Shares Outstanding: 577,471
• 10 Day Avg. Volume: 759,420
• 30 Day Avg. Volume: 283,737
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.63
• Price to Cash Flow (P/CF): -1.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The overall score of 44 reflects significant challenges faced by Elevai Labs, particularly in terms of profitability and cash flow. While revenue growth is strong, the lack of earnings and negative cash flow weigh heavily on the financial outlook. Technical indicators suggest mixed signals, with some short-term positive signs but overall bearish trends. The negative P/E ratio and absence of a dividend further underscore valuation concerns.

ELEVAI Labs Inc. Business Overview & Revenue Model

Company Description

ELEVAI Labs Inc. (ELAB) is a biotechnology company that operates in the skincare industry, focusing on the development of innovative skincare products utilizing exosome technology. The company's core products are centered around regenerative skincare solutions that aim to enhance skin health and aesthetics through advanced scientific research and development.

How the Company Makes Money

ELEVAI Labs Inc. makes money through the sale of its proprietary exosome-based skincare products. These products are distributed through various channels, including direct-to-consumer sales via the company's website, partnerships with dermatology clinics, and collaborations with skincare professionals. Additionally, the company may generate revenue from licensing agreements and strategic partnerships with other entities in the skincare and biotechnology sectors, leveraging its proprietary technology and research capabilities.

ELEVAI Labs Inc. Financial Statement Overview

Summary

Elevai Labs Inc. is experiencing robust revenue growth, a positive indicator of market traction. Nonetheless, profitability and cash flow remain critical challenges, impacting overall financial health. While the balance sheet reflects moderate leverage and a solid equity base, sustained losses and cash flow issues call for strategic adjustments. Continued focus on improving operational efficiencies and reducing losses will be crucial for long-term sustainability.

Income Statement

Elevai Labs Inc. has shown impressive revenue growth, advancing from $827 in 2021 to $1,712,595 in 2023, indicating a strong growth trajectory. However, profitability remains a concern with negative net income, EBIT, and EBITDA margins, reflecting ongoing operational challenges and high costs relative to revenue. The gross profit margin is also pressured, suggesting room for improvement in cost management.

Balance Sheet

The company's balance sheet shows a modest debt-to-equity ratio, with total debt relatively low compared to stockholders' equity. The equity ratio is healthy, indicating a substantial portion of assets funded by equity. However, accumulated losses impact overall financial strength, with ROE deeply negative due to persistent net losses. This positions Elevai Labs with a stable financial footing but highlights the need for improved profitability.

Cash Flow

Elevai Labs faces negative operating and free cash flows, signaling cash burn issues. Despite a substantial increase in financing cash flow, reliance on external funding is evident. The negative free cash flow growth rate suggests ongoing challenges in generating cash from operations, underscoring the need for enhanced cash management and operational efficiency.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.45M	1.71M	766.28K	827.00	0.00
	Gross Profit
1.72M	1.13M	442.27K	-2.02K	0.00
	EBIT
-4.17M	-3.67M	-1.79M	-785.06K	-221.84K
	EBITDA
-4.63M	-4.27M	-1.78M	-782.30K	-1.07K
	Net Income Common Stockholders
-5.47M	-4.30M	-1.80M	-784.74K	-222.91K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.15M	3.33M	1.15M	411.86K	13.35K
	Total Assets
1.89M	5.19M	1.89M	666.25K	17.02K
	Total Debt
283.22K	210.49K	283.22K	0.00	24.00K
	Net Debt
-871.68K	-3.12M	-871.68K	-411.86K	10.65K
	Total Liabilities
760.87K	1.36M	760.87K	215.62K	40.61K
	Stockholders Equity
1.13M	3.83M	1.13M	450.63K	-23.59K
Cash Flow		Free Cash Flow
-6.05M	-4.57M	-1.62M	-693.41K	-217.16K
	Operating Cash Flow
-5.87M	-4.56M	-1.59M	-660.93K	-217.16K
	Investing Cash Flow
-171.48K	-11.19K	-32.03K	-32.48K	0.00
	Financing Cash Flow
12.00M	6.74M	2.36M	1.09M	238.28K

ELEVAI Labs Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELAB, the sentiment is Negative. The current price of 4.89 is below the 20-day moving average (MA) of 6.14, below the 50-day MA of 10.42, and below the 200-day MA of 255.25, indicating a bearish trend. The MACD of -1.77 indicates Negative momentum. The RSI at 35.00 is Neutral, neither overbought nor oversold. The STOCH value of 35.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELAB.

ELEVAI Labs Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	68 Neutral	$1.09B	19.28	19.46%	―	19.07%	―
Sector *	55 Neutral	$4.58B	-19.70	-4.70%	5.70%	27.38%	-68.17%
VERU	46 Neutral	$75.62M	―	-80.11%	―	-7.43%	69.03%
QDEL	46 Neutral	$2.42B	―	-50.74%	―	-7.03%	-20233.78%
ELAB	44 Neutral	$2.85M	―	-130.35%	―	―	―
AXDX	39 Underperform	$26.55M	―	110.26%	―	-2.99%	59.87%
TTOO	35 Underperform	$3.41M	―	366.81%	―	-30.19%	97.74%